文章：

急性白血病中的微小残留病：从急性早幼粒细胞白血病中汲取的经验教训

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia

原文发布日期：20 September 2024

DOI: 10.3390/cancers16183208

类型: Article

开放获取: 是

英文摘要：

Introduction:Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality.Current Treatment Paradigms and Lessons Learned from APL:Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve the outcomes of these challenging diseases.Does the BM Microenvironment Play a Role in MRD?:In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.

摘要翻译： 

引言：分子生物学、聚合酶链反应（PCR）及下一代测序（NGS）技术的进步，已将微小残留病（MRD）从一个理论概念转变为可测量的现实。当前治疗模式与从APL中获得的经验：急性早幼粒细胞白血病（APL）引领了这一转变，最初利用PCR检测缓解期患者的MRD，近年来更通过现代治疗策略力求彻底清除MRD。在此过程中，我们获得了宝贵的见解，若将其应用于其他类型的急性白血病，有望显著改善这些难治性疾病的预后。骨髓微环境在MRD中的作用：本文综述了MRD在急性白血病治疗中的当前应用，并深入探讨了导致MRD持续存在的生物学过程，包括其与白血病干细胞的重叠性以及骨髓微环境的作用。

原文链接：

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia